

4<sup>th</sup> February, 2026

**BSE Limited**

P.J. Towers, Dalal Street, Fort,  
Mumbai- 400 001  
BSE scrip code: 543635

**National Stock Exchange of India Limited**

Exchange Plaza, Bandra-Kurla Complex,  
Bandra (East), Mumbai – 400 051  
NSE symbol: PPLPHARMA

**Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('SEBI Listing Regulations') - Receipt of closure directions for Company's Dahej site**

Dear Sir / Madam,

Pursuant to the provisions of Regulation 30 of the SEBI Listing Regulations, we hereby inform that the Company has received a notice on 3<sup>rd</sup> February, 2026, from the Gujarat Pollution Control Board ('GPCB') directing closure of operations at the Company's plant located at Plot No. D-2/11/A/1, GIDC Dahej, Taluka - Vagra, District - Bharuch, 392130, Gujarat, India, within a maximum timeline of 48 hours from receipt thereof, to ensure safe shut down of industrial activity. The notice alleges violations under Section 33-A of the Water (Prevention and Control of Pollution) Act, 1974.

GPCB has also directed submission of a bank guarantee of Rs. 15,00,000/- with a validity of one year. Apart from this, financial and operational impact is not ascertainable at this point in time.

The Company is of the opinion that the alleged violation is unsubstantiated and is in the process of filing an urgent Writ Petition with the Gujarat High Court seeking an expedited intervention to reverse the directions contained in said notice.

The Company believes in the merits of its technical and legal position and reiterates its commitment to maintain the highest standards of environmental compliance.

Kindly take the above on record.

Sincerely,

For **Piramal Pharma Limited**

**Tanya Sanish**  
**Company Secretary**

**Piramal Pharma Limited**

CIN: L24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India  
T +91 22 3802 3000 / 4000; Email: shareholders.ppl@piramal.com

[piramalpharma.com](http://piramalpharma.com)